Robert Aiello, Ph.D.
Cybrexa Biology Director
Robert Aiello has more than 26 years of experience and accomplishments in all phases of drug discovery and development from justification, identification and prosecution of therapeutic targets, pharmacological profiling, and advancement of compounds through development and Drug Safety. He most recently served as Senior Director of Biology for a newly formed company, Karos Pharmaceuticals and was responsible for overseeing biology efforts in the identification and development of small molecules for the treatment of pulmonary arterial hypertension, NASH, and other orphan diseases. Prior to joining Karos, he had a 20-year career in the Cardiovascular & Metabolic Disease Unit of Pfizer Pharmaceuticals where he directed biological research in metabolic diseases with a focus on diabetes, lipoprotein metabolism, and atherosclerosis. Bob joined Pfizer after a post-doctoral fellowship at the University of Wisconsin where he conducted extensive research in the area of lipoprotein metabolism and in vivo kinetics of apolipoproteins.
Bob has co-authored more than 30 scientific publications and holds 5 US Patents for the treatment of Atherosclerosis. He has extensive experience with numerous animal models of metabolic diseases and inflammation including transgenic and knockout mice, rats, swine, rabbits, hamsters, guinea pigs and marmosets, and his work has influenced many aspects of research in the field of atherosclerosis and metabolic diseases involving lipid transport and efflux.
5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731